BR112019025478A8 - Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer - Google Patents

Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer

Info

Publication number
BR112019025478A8
BR112019025478A8 BR112019025478A BR112019025478A BR112019025478A8 BR 112019025478 A8 BR112019025478 A8 BR 112019025478A8 BR 112019025478 A BR112019025478 A BR 112019025478A BR 112019025478 A BR112019025478 A BR 112019025478A BR 112019025478 A8 BR112019025478 A8 BR 112019025478A8
Authority
BR
Brazil
Prior art keywords
regorafenib
inhibitors
combination
cancer treatment
cancer
Prior art date
Application number
BR112019025478A
Other languages
English (en)
Other versions
BR112019025478A2 (pt
Inventor
Hoff Sabine
Röse Lars
Zopf Dieter
Kiessling Fabian
Lederle Wiltrud
Doleschel Dennis
Original Assignee
Bayer Ag
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Healthcare Llc filed Critical Bayer Ag
Publication of BR112019025478A2 publication Critical patent/BR112019025478A2/pt
Publication of BR112019025478A8 publication Critical patent/BR112019025478A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAÇÃO DE REGORAFENIB E INIBIDORES DE PD-1/PD-L1(2) PARA TRATAMENTO DE CÂNCER. A presente invenção refere-se a composições farmacêuticas e combinações que compreendem regorafenib ou seu hidrato, solvato, metabólito ou sal aceitável farmaceuticamente ou um polimorfo e um inibidor de PD-1/PD-L1(2) para tratar, prevenir ou controlar doenças e condições, inclusive distúrbios hiperproliferativos, como câncer em humanos e outros mamíferos.
BR112019025478A 2017-06-02 2018-05-25 Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer BR112019025478A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP17174169.7 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
BR112019025478A2 BR112019025478A2 (pt) 2020-06-23
BR112019025478A8 true BR112019025478A8 (pt) 2022-12-06

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025478A BR112019025478A8 (pt) 2017-06-02 2018-05-25 Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer

Country Status (16)

Country Link
US (4) US11951166B2 (pt)
EP (2) EP3630112B9 (pt)
JP (2) JP7303122B2 (pt)
KR (1) KR102673422B1 (pt)
CN (3) CN117582495A (pt)
AU (2) AU2018276273B2 (pt)
BR (1) BR112019025478A8 (pt)
CA (1) CA3065125A1 (pt)
DK (1) DK3630112T3 (pt)
FI (1) FI3630112T3 (pt)
IL (1) IL270948A (pt)
LT (1) LT3630112T (pt)
MX (1) MX2023001721A (pt)
PT (1) PT3630112T (pt)
RS (1) RS65488B1 (pt)
WO (1) WO2018219807A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117582495A (zh) * 2017-06-02 2024-02-23 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2628881A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
RS57875B1 (sr) * 2012-09-25 2018-12-31 Bayer Pharma AG Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
MX2016010082A (es) * 2014-02-04 2016-10-07 Pfizer Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
EP3132802B1 (en) 2014-02-21 2020-06-17 IDAC Theranostics, Inc. Therapeutic agent for solid cancer
CN107072984B (zh) 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
SG11201700978SA (en) * 2014-08-19 2017-03-30 Univ Okayama Nat Univ Corp Method for enhancing immune cell function and method for assessing immune cell multifunctionality
ES2774448T3 (es) * 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
CN106999582A (zh) 2014-11-13 2017-08-01 约翰·霍普金斯大学 检查点阻断和微卫星不稳定性
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
WO2017210119A1 (en) 2016-06-03 2017-12-07 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
CN117582495A (zh) * 2017-06-02 2024-02-23 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
WO2018226580A2 (en) * 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use

Also Published As

Publication number Publication date
EP3630112A1 (en) 2020-04-08
RS65488B1 (sr) 2024-05-31
FI3630112T3 (fi) 2024-05-02
PT3630112T (pt) 2024-04-23
US20220133888A1 (en) 2022-05-05
CN110662540A (zh) 2020-01-07
JP7475402B2 (ja) 2024-04-26
MX2023001721A (es) 2023-02-22
CN117582495A (zh) 2024-02-23
WO2018219807A1 (en) 2018-12-06
CN110662540B (zh) 2024-01-26
EP4342542A2 (en) 2024-03-27
IL270948A (en) 2020-01-30
AU2018276273A1 (en) 2019-12-12
KR102673422B1 (ko) 2024-06-07
US11951166B2 (en) 2024-04-09
EP4342542A3 (en) 2024-06-05
CA3065125A1 (en) 2018-12-06
US11517622B2 (en) 2022-12-06
JP2020521786A (ja) 2020-07-27
BR112019025478A2 (pt) 2020-06-23
US20200188372A1 (en) 2020-06-18
KR20200011971A (ko) 2020-02-04
RU2019143599A3 (pt) 2021-09-10
AU2023282197A1 (en) 2024-01-04
EP3630112B1 (en) 2024-01-31
JP2022169780A (ja) 2022-11-09
US20200179354A1 (en) 2020-06-11
LT3630112T (lt) 2024-05-10
CN117899212A (zh) 2024-04-19
RU2019143599A (ru) 2021-07-09
DK3630112T3 (da) 2024-04-22
AU2018276273B2 (en) 2023-12-21
JP7303122B2 (ja) 2023-07-04
EP3630112B9 (en) 2024-06-26
US20200155674A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
CR20190394A (es) Compuestos de inhibidores de autotaxina
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
BR112017018234A2 (pt) inibidores de pd-1 / pd-l1 para o tratamento de câncer
BR112017027951A2 (pt) composto inibitório de brk
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019006987A2 (pt) inibidores de receptor de glicocorticoide
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
BR112019004684A2 (pt) combinação de agonistas de fxr
ZA201901367B (en) Inhibition of olig2 activity

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE LLC (US)